Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MPO | P05164 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.51 |
| ▸ | ECE1 | P42892 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31165850 | 1.00 | ACE (0.54) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL30522757 | 1.00 | ACE (0.54) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL31165874 | 1.00 | ACE (0.54) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL31193784 | 1.00 | ACE (0.54) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL29483776 | 0.99 | ACE (0.55) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL30305288 | 0.98 | KDM4E (0.52) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL30148431 | 0.98 | KDM4E (0.52) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL30305304 | 0.98 | KDM4E (0.52) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL29799999 | 0.98 | KDM4E (0.52) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL29732484 | 0.98 | KDM4E (0.52) | ACEKDM4EMEN1LMNAMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570697-B2 | Cyclic peptide useful in the treatment of cancer | SYNTHERIX LIMITED (GB) | 2026-03-10 | — | — | US | disclosed |
| EP-3947418-B1 | PEPTIDES AND USE THEREOF | SYNTHERIX LTD (GB) | 2024-04-03 | — | — | EP | disclosed |
| US-20220242914-A1 | PEPTIDES AND USE THEREOF | SYNTHERIX LIMITED (GB) | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570697-B2 | Cyclic peptide useful in the treatment of cancer | NPR1, NPR3, PTMS | ACE 2619/4885KDM4E 1131/4885MEN1 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.